Effects of dopaminergic agents and of an NMDA receptor antagonist on motor coordination in Lurcher mutant mice

Pharmacology Biochemistry and Behavior

Volumn 63, Issue 2, 1999, Pages 213-219

  Thullier, F ^a   Lalonde, R ^b   Lestienne, F ^a  

^a CNRS   (France)

^b UNIVERSITÉ DE ROUEN   (France)

Author keywords

Ataxia; Cerebellum; Dopamine receptor; Lurcher; Motor coordination; NMDA receptor

Indexed keywords

3 ALLYL 2,3,4,5 TETRAHYDRO 1 PHENYL 1H 3 BENZAZEPINE 7,8 DIOL; BENSERAZIDE; DEXTROMETHORPHAN; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA METHYL ESTER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO;

ANIMAL MODEL; ARTICLE; CEREBELLAR ATAXIA; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOTOR ACTIVITY; MOTOR COORDINATION; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL;

ATAXIA;

EID: 0032906334     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00228-7     Document Type: Article

References (34)

1. Baunez C., Nieoullon A., Amalric M. N-methyl-D-aspartate receptor blockade impairs behavioural performance of rats in a reaction time task. New evidence for glutamatergic-dopaminergic interactions in the striatum Neuroscience. 61:1994;521-531.
2. Beninger R.J. The role of dopamine in locomotor activity and learning. Brain Res. Rev. 6:1983;173-196.
3. Botez M.I., Young S.N., Botez T., Pedraza O.L. Treatment of heredo-degenerative ataxias with amantadine hydrochloride. Can. J. Neurol. Sci. 18:1991;307-311.
4. Botez M.I., Botez-Marquard T., Goyette K., Elie R., Pedraza O.-L., Lalonde R. Amantadine hydrochloride treatment in heredodegenerative ataxias. A double-blind study J. Neurol. Neurosurg. Psychiatry. 61:1996;259-264.
5. Caddy K.W.T., Biscoe T.J. Structural and quantitative studies on the normal C3H and Lurcher mutant mice. Philos. Trans. R. Soc. Lond. Ser. B. 287:1979;167-201.
6. 2 mediated behaviors in intact rats. Psychopharmacology (Berlin). 123:1996;187-190.
7. Danysz W., Essmann U., Bresink I., Wilke R. Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol. Biochem. Behav. 38:1994;111-117.
8. Diana G., Sagratella S. Different capability of NMDA antagonists to affect locomotor exploratory activity of mice in a computerized on-line openfield test. Pharmacol. Biochem. Behav. 48:1994;291-295.
9. Engber T.M., Anderson J.J., Boldry R.C., Papa S.M., Kuo S., Chase T.N. Excitatory amino acid receptor antagonists modify regional cerebral metabolic responses to levodopa in 6-hydroxytryptamine-lesioned rats. Neuroscience. 59:1994;389-399.
10. Fortier P.A., Smith A.M., Rossignol S. Locomotor deficits in the mutant mouse Lurcher. Exp. Brain Res. 66:1987;271-286.
11. Gerfen C.R. Dopamine receptor function in the basal ganglia. Clin. Neuropharmacol. 18:1995;S162-S177.
12. Goetz C.G., Tanner C.M., Klawans H.L. The pharmacology of olivopontocerebellar atrophy. Duvoisin R.C., Plaitakis A. The olivopontocerebellar atropies. 1984;143-148 Raven Press, New York.
13. Greenamyre J.T., Eller R.V., Zhang Z., Ovadia A., Kurlan R., Gash D.M. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann. Neurol. 35:1994;655-661.
14. Heckroth J.A., Eisenman M. Olivary morphology and olivocerebellar topography in adult Lurcher mutant mice. J. Comp. Neurol. 312:1991;641-651.
15. Huang Y.P., Plaitakis A. Morphological changes of olivopontocerebellar atrophy in computed tomography and comments on its pathogenesis. Duvoisin R.C., Plaitakis A. The olivopontocerebellar atrophies. 1984;39-85 Raven Press, New York.
16. Ikai Y., Takada M., Shinonaga Y., Mizuno N. Dopaminergic and non-dopaminergic neurons in the ventral tegmental area of the rat project, respectively, to the cerebellar cortex and deep cerebellar nuclei. Neuroscience. 51:1992;719-728.
17. Irifune M., Shimizu T., Nomoto M., Fukuda T. Involvement of N-methyl-D-aspartate receptors in noncompetitive NMDA receptor antagonist-induced hyperlocomotion in mice. Pharmacol. Biochem. Behav. 51:1995;291-296.
18. Kinoshita K., Watanabe Y., Asai H., Yamamura M., Matsuoko Y. Anti-ataxic effects of TRH and its analogues, TA-0910, in rolling mouse Nagoya by metabolic normalization of the ventral tegmental area. Br. J. Pharmacol. 116:1995;3274-3278.
19. Klockgether T., Turski L. NMDA antagonists potentiate antiparkinsonian actions of L-Dopa in monoamine-depleted rats. Ann. Neurol. 28:1990;539-546.
20. Lalonde R. Pharmacotherapy in animals with hereditary cerebellar disease. Pandalai S.G. Recent research development in neurochemistry, vol l. 1996;55-88 Research Singpost, Trivandrutt.
21. Lalonde R., Botez-Marquard T. The neurobiological basis of movement initiation. Rev. Neurosci. 8:1997;35-54.
22. Lalonde R., Botez M.I., Joyal C.C., Caumartin M. Motor abnormalities in Lurcher mutant mice. Physiol. Behav. 51:1992;523-525.
23. Lalonde R., Joyal C.C., Guastavino J.-M., Côté C., Botez M.I. Amantadine and ketamine-induced improvement of motor coordination in Lurcher mutant mice. Rest. Neurol. Sci. 5:1993;367-370.
24. Leviel V., Gobert A., Guibert B. The glutamate-mediated release of dopamine in the rat striatum. Further characterization of the dual excitatory-inhibitory function Neuroscience. 39:1990;305-312.
25. Meyer M.E., Shults J.M. Dopamine D1 receptor family agonists, SK&F 38393, SK&F 77434 and SK&F 82958, differentially affect locomotor activities in rats. Pharmacol. Biochem. Behav. 46:1993;269-274.
26. Panagopoulos N.T., Papadopoulos G.C., Matsokis N.A. Dopaminergic innervation and binding in the rat cerebellum. Neurosci. Lett. 130:1991;208-212.
27. Reader T.A., Strazielle C., Botez M.I., Lalonde R. Brain dopamine and amino acid concentrations in Lurcher mutant mice. Brain Res. Bull. 45:1998;489-493.
28. Snider R.S., Maiti A., Snider S.R. Cerebellar pathways to ventral midbrain and nigra. Exp. Neurol. 53:1976;714-728.
29. 125I]RTI-121 quantitative autoradiography. Neurochem. Int. 32:1998;61-68.
30. Svensson A., Carlsson M.L., Carlsson A. Interaction between glutamatergic and dopaminergic tone in the nucleus accumbens of mice. Evidence for a dual glutamatergic function with respect to psychomotor control J. Neural Transm. 88:1992;235-240.
31. Trouillas P. Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. Ital. J. Neurol. Sci. 5:1984;253-266.
32. Turski L., Turski W.A. Towards an understanding of the role of glutamate in neurodegenerative disorders. energy metabolism and neuropathology Experientia. 49:1993;1064-1072.
33. Wu M., Brudzynski S.M., Mogenson G.J. Functional interaction of dopamine and glutamate in the nucleus accumbens in the regulation of locomotion. Can. J. Physiol. Pharmacol. 71:1993;407-413.
34. Zuo J., De Jager P.L., Takahashi K.A., Jiang W., Linden D.J., Heintz N. Neurodegeneration in Lurcher mice caused by mutation in delta2 glutamate receptor gene. Nature. 388:1997;769-773.